Navigation Links
Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders
Date:7/22/2014

everal metabolic parameters.  The trial's primary efficacy end point was a reduction in liver fat content, without consideration of inflammation or fibrosis. The secondary efficacy end points measured differences between the aramchol-treated group and the placebo group with respect to alterations of liver enzyme levels, levels of adiponectin, homeostasis model assessment scores, and endothelial function.  All endpoints were met and there were no notable changes in biochemical, hematological, cardiovascular or other safety parameters, or any observable serious or drug-related adverse events in the 58 patients who completed the trial either during the three-month treatment period or during the subsequent recovery period.  Galmed further confirmed the appropriateness of a single daily dose of aramachol by pharmacokinetic analysis.

About Galmed Pharmaceuticals Ltd.

Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs.  Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.

Cautionary Note on Forward-Looking Statements

This press release includes forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors," included in the registration statement on Form F-1 (File No. 333 -193792), initially filed with the Securities and Exchange Commission, or the SEC, on February 6, 2014 and declared eff
'/>"/>

SOURCE Galmed Pharmaceuticals Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014
2. Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board
3. Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder
4. WaferGen Bio-Systems Announces Appointment of Ivan Trifunovich as Chairman of the Board; Joel Kanter to Serve as Lead Independent Director
5. Radyalis Announces Next Generation Of Monte Carlo Proton Therapy Planning For Advanced Radiation Cancer Treatment
6. Richmond Private Equity Group announces joint venture with Taking You Forward Inc.
7. Depomed Announces District Court Order in ANDA Litigation
8. Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
9. JDRF Partner ViaCyte Announces Key Project Milestone to Advance Innovative Encapsulated Cell Replacement Therapy Product for Type 1 Diabetes
10. Fragile Kids Foundation Announces $125,000 Grant from the James M. Cox Foundation
11. BioLife Solutions Announces Manufacturing Agreement With Somahlution LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 2014   DaVita HealthCare Partners Inc.  (NYSE: ... largest and most innovative health care communities, today ... DaVita Clinical Research  (DCR) and  HealthCare Partners Clinical Research ... extensive clinical research and data analytics services, specifically ... end-stage renal disease (ESRD), as well as primary ...
(Date:12/13/2014)... 11, 2014 Research and Markets ... the "Drug Injection Devices to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769 As new drugs ... list of health conditions, drug developers have increasingly ... administration process and increase the efficiency and reliability ...
(Date:12/13/2014)... Mindray Medical International Limited ("Mindray", NYSE: ... of medical devices worldwide, today announced shareholder resolutions adopted ... Hong Kong on December 10, ... to re-elect incumbent directors Li Xiting and Kern Lim, ... not re-elect Peter Wan as a director. ...
Breaking Medicine Technology:DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2
... Sept. 1, 2011 Lifetime Products, Inc. -- a ... goods equipment, outdoor storage sheds, and lawn and garden ... product depth and adding a new Health and Wellness ... and Wellness category will feature products like the award-winning ...
... Corporation (NASDAQ: ANGN ) today reported financial results ... Angeion reported revenues of $6.8 million compared to ... incurred a net loss of $81,000, or $(0.02) per diluted ... share in the comparable quarter last year. Financial results for ...
Cached Medicine Technology:Lifetime Products Enters New Product Category: Health and Wellness 2Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 2Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 3Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 4Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 5Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 6Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 7
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Host Investor Conference Call on Thursday, May 14, ... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ... development and commercialization of medically important, novel pharmaceutical ... renal disease and cancer (the "Company"), today announced ...
... finds , , WEDNESDAY, May 13 (HealthDay News) -- ... symptoms of bronchiolitis -- a virus-triggered condition that causes ... may reduce the risk of hospitalization by more than ... babies back to normal feeding sooner than either treatment ...
... Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: ... therapeutics for disease indications with large markets, today announced ... 2009., Selected Highlights, ... fiscal 2009 and up to the date of this ...
... start of dementia , , WEDNESDAY, May 13 (HealthDay News) ... the risk for developing Alzheimer,s disease in older people. ... well as complex physiological testing, may not be practical for ... fairly easy, such as age and mental status exams. We ...
... ROCHESTER, N.Y., May 13 A multi-million dollar ... to launch the University of Rochester ... recognized, comprehensive center for investigating and treating neurological ... dystrophy, stroke, and trauma to the brain and ...
... ANGELES, May 13 Runners, cyclists, fans and anyone interested ... the Memorial Day weekend leading up to the 24th Los ... Memorial Day, May 25. Coming up:>> Saturday, May 23: Run/Ex/09 ... Run/Ex/09, will open in the South Hall of the Los ...
Cached Medicine News:Health News:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results 2Health News:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results 3Health News:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results 4Health News:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results 5Health News:Combo Treatment Eases Wheezing in Babies 2Health News:Combo Treatment Eases Wheezing in Babies 3Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 2Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 3Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 4Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 5Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 6Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 7Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 8Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 9Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 10Health News:15-Point Test Gauges Alzheimer's Risk 2Health News:$10 Million Gift to Transform Neuromedicine at URMC 2Health News:$10 Million Gift to Transform Neuromedicine at URMC 3Health News:$10 Million Gift to Transform Neuromedicine at URMC 4Health News:$10 Million Gift to Transform Neuromedicine at URMC 5Health News:Full Calendar of Activities for 24th Los Angeles Marathon This Memorial Day Weekend 2
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Each slide contains Giardia lamblia trophozoites applied as a mono-layer to the side....
... wells: a positive control containing ... in simulated sputum and a ... subsp. albus ATCC ® 3004 ... Control Slides should be stained ...
... With 384 Well Plate Capability The ... the original Equalizerexpandable and equal tip spacing, choice ... calibration capabilities. In addition, this model allows you ... for loading and accessing many gels and for ...
Medicine Products: